Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more ...

The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise ...

The $2.2 billion deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Under the agreement, Septerna could receive up to approximately $2.2 billion, including over $200 million in upfront and near-term milestone payments. Additionally, Septerna will be eligible for ...

The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 151.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

Analysts' ratings for Septerna SEPN over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a snapshot of their recent ratings, showcasing how ...